Moreover, fewer MAFLD patients had cirrhosis (50.7% vs 71.3%), preoperative alpha fetoprotein concentration ≥ 400 ng/mL (23.9% vs 42.2%), tumor size ≥ 5 cm (49.3% vs 61.6%), mulinodular (10.4% vs 22.5%), microvascular invasion (41.8% vs 56.7%), and receiving major hepatectomy (19.4% vs 34.1%) or adjuvant transarterial chemoembolization (32.8% vs 55.0%) than CHB patients. The gene discussed is AFP; the disease is neoplasm.